China Resources Boya Bio-pharmaceutical, a key player in blood products and medical aesthetics, has alerted investors to a dramatic profit drop for 2025, forecasting net profit attributable to shareholders at RMB105 million to RMB136.5 million—down over 65% from RMB397 million in 2024. Excluding non-recurring gains, the company anticipates an underlying net loss of RMB7.5 million to RMB15 million, highlighting intensifying pressures in China's biotech sector.
Impairments Drive the Downturn
The profit slump stems largely from a slump in the hyaluronic acid medical aesthetics market, a staple for dermal fillers and anti-aging treatments. Management cited roughly RMB300 million in impairments on franchise rights and goodwill linked to the November 2024 acquisition of Green Cross HK Holdings. Additional hits include RMB80 million from inventory revaluation and elevated depreciation and amortization from the deal.
- Net profit forecast: RMB105-136.5 million (vs. RMB397 million prior year)
- Underlying loss: RMB7.5-15 million (excluding one-offs)
- Non-recurring gains: ~RMB120 million from subsidies and investments
Revenue Growth Amid Margin Erosion
Despite challenges, operating revenue is projected to climb 10% to 25%, fueled by the Green Cross integration, which bolsters the company's hyaluronic acid portfolio. However, the blood products segment—CR Boya's traditional stronghold—faces headwinds from China's centralized procurement policies, payment reforms, stricter medical insurance controls, and fierce competition. These reforms, aimed at curbing healthcare costs, have squeezed gross margins across the industry, forcing biopharma firms to rethink pricing and efficiency.
Broader Implications for Biotech in China
This warning underscores vulnerabilities in China's medical aesthetics boom, once propelled by rising consumer demand for non-invasive beauty enhancements but now cooling amid regulatory scrutiny and economic slowdowns. Hyaluronic acid demand has softened as clinics grapple with oversupply and shifting preferences toward conservative treatments. For CR Boya and parent China Resources Pharmaceutical, it signals a pivot needed toward cost controls and diversified revenue, amid a healthcare landscape prioritizing affordability over premium pricing. Investors should watch for strategic divestments or R&D shifts to navigate these operational headwinds.
